Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Adv Mater ; 35(41): e2304022, 2023 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-37358536

RESUMEN

Electrochemical oxygen evolution reaction (OER) kinetics are heavily correlated with hybridization of the transition metal d-orbital and oxygen intermediate p-orbital, which dictates the barriers of intermediate adsorption/desorption on the active sites of catalysts. Herein, a strategy is developed involving strain engineering and coordination regulation to enhance the hybridization of Ni 3d and O 2p orbitals, and the as-synthesized Ni-2,6-naphthalenedicarboxylic acid metal-organic framework (DD-Ni-NDA) nanosheets deliver a low OER overpotential of 260 mV to reach 10 mA cm-2 . By integrating an alkaline anion exchange membrane electrolyzer and Pt/C electrode, 200 and 500 mA cm-2 current densities are reached with cell voltages of 1.6 and 2.1 V, respectively. When loaded on a BiVO4 photoanode, the nanosheet enables highly active solar-driven water oxygen. Structural characterizations together with theoretical calculations reveal that the spin state of the centre Ni atoms is regulated by the tensile strain and unsaturated coordination defects in DD-Ni-NDA, and such spin regulation facilitates spin-dependent charge transfer of the OER. Molecular orbital hybridization analysis reveals the mechanism of OH* and OOH* adsorption energy regulation by changes in the DD-Ni-NDA spin state, which provides a deeper understanding of the electronic structure design of catalysts for the OER.

2.
Nat Commun ; 13(1): 6486, 2022 Oct 30.
Artículo en Inglés | MEDLINE | ID: mdl-36309525

RESUMEN

Two-dimensional metal-organic frameworks (MOFs) have been explored as effective electrocatalysts for hydrogen evolution reaction (HER). However, the sluggish water activation kinetics and structural instability under ultrahigh-current density hinder their large-scale industrial applications. Herein, we develop a universal ligand regulation strategy to build well-aligned Ni-benzenedicarboxylic acid (BDC)-based MOF nanosheet arrays with S introducing (S-NiBDC). Benefiting from the closer p-band center to the Fermi level with strong electron transferability, S-NiBDC array exhibits a low overpotential of 310 mV to attain 1.0 A cm-2 with high stability in alkaline electrolyte. We speculate the newly-constructed triangular "Ni2-S1" motif as the improved HER active region based on detailed mechanism analysis and structural characterization, and the enhanced covalency of Ni-O bonds by S introducing stabilizes S-NiBDC structure. Experimental observations and theoretical calculations elucidate that such Ni sites in "Ni2-S1" center distinctly accelerate the water activation kinetics, while the S site readily captures the H atom as the optimal HER active site, boosting the whole HER activity.

3.
World J Gastroenterol ; 23(43): 7666-7677, 2017 Nov 21.
Artículo en Inglés | MEDLINE | ID: mdl-29209108

RESUMEN

Cirrhosis develops from liver fibrosis and is the severe pathological stage of all chronic liver injury. Cirrhosis caused by hepatitis B virus and hepatitis C virus infection is especially common. Liver fibrosis and cirrhosis involve excess production of extracellular matrix, which is closely related to liver sinusoidal endothelial cells (LSECs). Damaged LSECs can synthesize transforming growth factor-beta and platelet-derived growth factor, which activate hepatic stellate cells and facilitate the synthesis of extracellular matrix. Herein, we highlight the angiogenic cytokines of LSECs related to liver fibrosis and cirrhosis at different stages and focus on the formation and development of liver fibrosis and cirrhosis. Inhibition of LSEC angiogenesis and antiangiogenic therapy are described in detail. Targeting LSECs has high therapeutic potential for liver diseases. Further understanding of the mechanism of action will provide stronger evidence for the development of anti-LSEC drugs and new directions for diagnosis and treatment of liver diseases.


Asunto(s)
Células Endoteliales/patología , Células Estrelladas Hepáticas/patología , Hepatitis Viral Humana/patología , Cirrosis Hepática/patología , Hígado/patología , Inhibidores de la Angiogénesis/farmacología , Inhibidores de la Angiogénesis/uso terapéutico , Animales , Citocinas/metabolismo , Modelos Animales de Enfermedad , Células Endoteliales/efectos de los fármacos , Células Endoteliales/metabolismo , Células Endoteliales/virología , Matriz Extracelular/metabolismo , Matriz Extracelular/patología , Hepacivirus/patogenicidad , Células Estrelladas Hepáticas/metabolismo , Células Estrelladas Hepáticas/virología , Virus de la Hepatitis B/patogenicidad , Hepatitis Viral Humana/diagnóstico , Hepatitis Viral Humana/tratamiento farmacológico , Hepatitis Viral Humana/virología , Humanos , Hígado/irrigación sanguínea , Hígado/citología , Hígado/virología , Cirrosis Hepática/diagnóstico , Cirrosis Hepática/tratamiento farmacológico , Cirrosis Hepática/virología , Neovascularización Patológica/tratamiento farmacológico , Neovascularización Patológica/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA